ACA
Avoro Capital Advisors’s Avidity Biosciences RNA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $200M | Sell |
7,050,000
-575,000
| -8% | -$16.3M | 3.51% | 8 |
|
|
2025
Q1 | $225M | Buy |
7,625,000
+125,000
| +2% | +$3.69M | 3.51% | 8 |
|
|
2024
Q4 | $218M | Buy |
7,500,000
+625,000
| +9% | +$18.2M | 3.08% | 12 |
|
|
2024
Q3 | $316M | Buy |
6,875,000
+370,000
| +6% | +$17M | 4.6% | 8 |
|
|
2024
Q2 | $266M | Buy |
6,505,000
+680,000
| +12% | +$27.8M | 3.54% | 12 |
|
|
2024
Q1 | $149M | Buy |
5,825,000
+3,315,000
| +132% | +$84.6M | 1.73% | 20 |
|
|
2023
Q4 | $22.7M | Hold |
2,510,000
| – | – | 0.31% | 37 |
|
|
2023
Q3 | $16M | Hold |
2,510,000
| – | – | 0.25% | 34 |
|
|
2023
Q2 | $27.8M | Hold |
2,510,000
| – | – | 0.38% | 30 |
|
|
2023
Q1 | $38.5M | Buy |
2,510,000
+460,000
| +22% | +$7.06M | 0.57% | 23 |
|
|
2022
Q4 | $45.5M | Buy |
2,050,000
+600,000
| +41% | +$13.3M | 0.68% | 23 |
|
|
2022
Q3 | $23.7M | Buy |
1,450,000
+150,000
| +12% | +$2.45M | 0.44% | 29 |
|
|
2022
Q2 | $18.9M | Hold |
1,300,000
| – | – | 0.37% | 30 |
|
|
2022
Q1 | $24M | Buy |
1,300,000
+70,000
| +6% | +$1.29M | 0.44% | 31 |
|
|
2021
Q4 | $29.2M | Buy |
1,230,000
+80,000
| +7% | +$1.9M | 0.5% | 31 |
|
|
2021
Q3 | $28.3M | Buy |
1,150,000
+605,000
| +111% | +$14.9M | 0.44% | 32 |
|
|
2021
Q2 | $13.5M | Hold |
545,000
| – | – | 0.23% | 38 |
|
|
2021
Q1 | $11.9M | Hold |
545,000
| – | – | 0.21% | 40 |
|
|
2020
Q4 | $13.9M | Hold |
545,000
| – | – | 0.24% | 36 |
|
|
2020
Q3 | $15.3M | Sell |
545,000
-40,000
| -7% | -$1.13M | 0.22% | 39 |
|
|
2020
Q2 | $16.5M | Buy |
+585,000
| New | +$16.5M | 0.33% | 36 |
|